Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application

Bulletin Express

02/13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.

According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1137162235"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137162235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137162235?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137162235","market":"us","top_or_hot":-1,"title":"Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.</p>\n<p>According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-02-13 18:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.</p>\n<p>According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"復星醫藥","start_time":0,"source_url":"","article_id":"1137162235","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137162235","pubTimestamp":1770976947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196)公告子公司新药注册申请受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for 「Significant Drugs Development」 in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.\nAccording to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}